
## Angelo Iacobino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2479158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Novel Putative Transposable Element Associated with the Subtype E5 Botulinum Toxin Gene Cluster of Neurotoxigenic Clostridium butyricum Type E Strains from China. International Journal of Molecular Sciences, 2022, 23, 906.	1.8	1
2	Activity of Drug Combinations against Mycobacterium abscessus Grown in Aerobic and Hypoxic Conditions. Microorganisms, 2022, 10, 1421.	1.6	4
3	Multiplex Real-Time Reverse-Transcription Polymerase Chain Reaction Assays for Diagnostic Testing of Severe Acute Respiratory Syndrome Coronavirus 2 and Seasonal Influenza Viruses: A Challenge of the Phase 3 Pandemic Setting. Journal of Infectious Diseases, 2021, 223, 765-774.	1.9	22
4	Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner. Microorganisms, 2021, 9, 255.	1.6	13
5	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Frontiers in Immunology, 2021, 12, 750386.	2.2	6
6	Drug-Resistant Tuberculosis 2020: Where We Stand. Applied Sciences (Switzerland), 2020, 10, 2153.	1.3	46
7	Laboratory management for SARS-CoV-2 detection: a user-friendly combination of the heat treatment approach and rt-Real-time PCR testing. Emerging Microbes and Infections, 2020, 9, 1393-1396.	3.0	39
8	The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	13
9	Revisiting problems and solutions to decrease Mycobacterium tuberculosis pyrazinamide false resistance when using the Bactec MGIT 960 system. Annali Dell'Istituto Superiore Di Sanita, 2019, 55, 51-54.	0.2	4
10	Use of probiotics in medical devices applied to some common pathologies. Annali Dell'Istituto Superiore Di Sanita, 2019, 55, 380-385.	0.2	3
11	Activity of DNA-targeted C8-linked pyrrolobenzodiazepine–heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions. Journal of Antibiotics, 2018, 71, 831-834.	1.0	3
12	Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009–2016. European Respiratory Journal, 2018, 52, 1800070.	3.1	16
13	Galleria mellonella as an in vivo model for assessing the protective activity of probiotics against gastrointestinal bacterial pathogens. FEMS Microbiology Letters, 2017, 364, .	0.7	27
14	Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	25
15	Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance. Journal of Clinical Microbiology, 2017, 55, 3552-3553.	1.8	4
16	Fighting tuberculosis by drugs targeting nonreplicating <i>Mycobacterium tuberculosis</i> bacilli. International Journal of Mycobacteriology, 2017, 6, 213.	0.3	29
17	Effects of Megaplasmid Loss on Growth of Neurotoxigenic Clostridium butyricum Strains and Botulinum Neurotoxin Type E Expression. Frontiers in Microbiology, 2016, 7, 217.	1.5	4
18	Activity of drugs against dormant Mycobacterium tuberculosis. International Journal of Mycobacteriology, 2016, 5, S94-S95.	0.3	11

#	Article	IF	CITATIONS
19	Pyrazinamide susceptibility testing: proposed new standard with the BACTEC <sup>TM</sup> MGIT <sup>TM</sup> 960 system. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1677-1680.	0.6	4
20	Drug-resistant tuberculosis in Naples, 2008-2013. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 603-607.	0.2	2
21	Structure and Genetic Content of the Megaplasmids of Neurotoxigenic Clostridium butyricum Type E Strains from Italy. PLoS ONE, 2013, 8, e71324.	1.1	9
22	Stenotrophomonas maltophilia strains from cystic fibrosis patients: Genomic variability and molecular characterization of some virulence determinants. International Journal of Medical Microbiology, 2011, 301, 34-43.	1.5	66
23	Interference of the CadC regulator in the arginine-dependent acid resistance system of Shigella and enteroinvasive E. coli. International Journal of Medical Microbiology, 2010, 300, 289-295.	1.5	20